期刊文献+

Transplantation of VEGF165-gene-transfected endothelial progenitor cells in the treatment of chronic venous thrombosis in rats 被引量:14

Transplantation of VEGF165-gene-transfected endothelial progenitor cells in the treatment of chronic venous thrombosis in rats
原文传递
导出
摘要 Background The organization and recanalization of thrombi is a dynamic and complex process. The aim of this research was to study the cotherapeutic effect of stem cell transplantation and gene transfection on chronic venous thrombosis. Methods We constructed a recombinant adenoviral vector carrying the vascular endothelial growth factor 165 (VEGF165) gene by using the pAdEasy system, which was subsequently identified and amplified. Simultaneously, endothelial progenitor cells (EPCs) were isolated from rat bone marrow using Ficoll, cultured in EBM-2MV medium, and identified. Then, the cells were transfected with the recombinant Ad-VEGF165. The EPCs were labeled with 1 ,1'-dioctadecyl-3,3,3',3'-tetramethylindocarbocyanine (Dil) before transplantation. A rat model of chronic vein thrombosis was developed by partial ligation of the inferior vena cava. The rats were randomly divided into 4 groups (n=25, each): A, Ad-VEGF165/EPC-transplantation group received 1 ml (10^6) of Ad-VEGF165/EPCs; B, EPC-transplantation group received 1 ml (10^6) of EPCs; C, Ad/EPC-transplantation group received 1 ml (10^6) of Ad/EPCs; D, control group received 1 ml of the transplantation medium. The thrombi and adjacent caval walls were harvested 28 days after transplantation; real-time quantitative polymerase chain reaction was used to detect the expression level of vascular endothelial growth factor (VEGF) mRNA; and western blotting was used to measure changes in VEGF protein expression. Hematoxylin-eosin staining and immunohistochemical staining were performed to detect recanalization. Neovascularization was detected by immunohistochemical staining using the antibody for von Willebrand factor (vWF), which is a component of endothelial cells.The capillary density was quantitatively determined by counting the capillaries under a high-power microscope. Results The Ad-VEGF165 was constructed, and bone-marrow-derived EPCs were cultivated and successfully identified. We determined the optimum transfection ratio that promoted the growth of EPCs. After transfection, the EPCs secreted the VEGF protein. After transplantation, the in vivo survival of EPCs and their differentiation into endothelial cells were determined by detecting the fluorescence associated with the Dil stain. VEGF mRNA was expressed in groups A, B, C and D after transplantation, and the VEGF mRNA level in group A was significantly higher than those in groups B, C and D (P〈0.05); the VEGF mRNA levels in groups B and C were significantly higher than those in group D (P〈0.05), and there was no statistical significance between the VEGF mRNA levels in groups B and C. The recanalization capillary density in group A was significantly higher than those in groups B, C (P 〈0.05) and D (P 〈0.01); the recanalization capillary densities in groups B and C were significantly higher than that in group D (P 〈0.05). Moreover, there was no statistical significant difference between the values for groups B and C. Conclusions The EPCs were successfully transfected by Ad-VEGF165. A suitable transfection ratio can improve the efficiency of EPCs and the possibility of promotion of angiogenesis after transplantation. Transfected EPCs caused accelerated organization and recanalization of vein thrombi. Background The organization and recanalization of thrombi is a dynamic and complex process. The aim of this research was to study the cotherapeutic effect of stem cell transplantation and gene transfection on chronic venous thrombosis. Methods We constructed a recombinant adenoviral vector carrying the vascular endothelial growth factor 165 (VEGF165) gene by using the pAdEasy system, which was subsequently identified and amplified. Simultaneously, endothelial progenitor cells (EPCs) were isolated from rat bone marrow using Ficoll, cultured in EBM-2MV medium, and identified. Then, the cells were transfected with the recombinant Ad-VEGF165. The EPCs were labeled with 1 ,1'-dioctadecyl-3,3,3',3'-tetramethylindocarbocyanine (Dil) before transplantation. A rat model of chronic vein thrombosis was developed by partial ligation of the inferior vena cava. The rats were randomly divided into 4 groups (n=25, each): A, Ad-VEGF165/EPC-transplantation group received 1 ml (10^6) of Ad-VEGF165/EPCs; B, EPC-transplantation group received 1 ml (10^6) of EPCs; C, Ad/EPC-transplantation group received 1 ml (10^6) of Ad/EPCs; D, control group received 1 ml of the transplantation medium. The thrombi and adjacent caval walls were harvested 28 days after transplantation; real-time quantitative polymerase chain reaction was used to detect the expression level of vascular endothelial growth factor (VEGF) mRNA; and western blotting was used to measure changes in VEGF protein expression. Hematoxylin-eosin staining and immunohistochemical staining were performed to detect recanalization. Neovascularization was detected by immunohistochemical staining using the antibody for von Willebrand factor (vWF), which is a component of endothelial cells.The capillary density was quantitatively determined by counting the capillaries under a high-power microscope. Results The Ad-VEGF165 was constructed, and bone-marrow-derived EPCs were cultivated and successfully identified. We determined the optimum transfection ratio that promoted the growth of EPCs. After transfection, the EPCs secreted the VEGF protein. After transplantation, the in vivo survival of EPCs and their differentiation into endothelial cells were determined by detecting the fluorescence associated with the Dil stain. VEGF mRNA was expressed in groups A, B, C and D after transplantation, and the VEGF mRNA level in group A was significantly higher than those in groups B, C and D (P〈0.05); the VEGF mRNA levels in groups B and C were significantly higher than those in group D (P〈0.05), and there was no statistical significance between the VEGF mRNA levels in groups B and C. The recanalization capillary density in group A was significantly higher than those in groups B, C (P 〈0.05) and D (P 〈0.01); the recanalization capillary densities in groups B and C were significantly higher than that in group D (P 〈0.05). Moreover, there was no statistical significant difference between the values for groups B and C. Conclusions The EPCs were successfully transfected by Ad-VEGF165. A suitable transfection ratio can improve the efficiency of EPCs and the possibility of promotion of angiogenesis after transplantation. Transfected EPCs caused accelerated organization and recanalization of vein thrombi.
出处 《Chinese Medical Journal》 SCIE CAS CSCD 2010年第4期471-477,共7页 中华医学杂志(英文版)
基金 This work was supported by a grant from the Natural Science Foundation of Jiangsu Province (No. BK2007055).
关键词 vascular endothelial growth factor endothelialprogenitor cell gene transfection ADENOVIRUS venous thrombosis vascular endothelial growth factor endothelialprogenitor cell gene transfection adenovirus venous thrombosis
  • 相关文献

参考文献5

二级参考文献43

  • 1Achen MG, Stacker SA. Molecular control of lymphatic metastasis. Ann N YAcad Sci 2008; 1131: 225-234.
  • 2Krishnan J, Kirkin V, Steffen A, Hegen M, Weih D, Tomarev S, et al. Differential in vivo and in vitro expression of vascular endothelial growth factor (VEGF)-C and VEGF-D in tumors and its relationship to lymphatic metastasis in immunocompetent rats. Cancer Res 2003; 63:713-722.
  • 3Schneider M, Buchler P, Giese N, Giese T, Wilting J, Buchler MW, et al. Role of lymphangiogenesis and lymphangiogenic factors during pancreatic cancer progression and lymphatic spread. Int J Oncol 2006; 28: 883-890.
  • 4Ridwelski K, Meyer F, Ebert M, Malfertheiner P, Lippert H. Prognostic parameters determining survival in pancreatic carcinoma and, in particular, after palliative treatment. Dig Dis 2001; 19: 85-92.
  • 5Stacker SA, Achen MG Jussila L, Baldwin ME, Alitalo K. Lymphangiogenesis and cancer metastasis. Nat Rev Cancer 2002; 2: 573-583.
  • 6Whitehurst B, Eversgerd C, Flister M, Bivens CM, Pickett B, Zawieja DC, et al. Molecular profile and proliferative responses of rat lymphatic endothelial cells in culture. Lymphat Res Biol 2006; 4:119-142.
  • 7Kaipainen A, Korhoned J, Mustonen T, van Hinsbergh VW, Fang GH, Dumont D, et al. Expression of the fms-like tyrosine kinase 4 gene becomes restricted to lymphatic endothelium during development. Proc Natl Acad Sci USA 1995; 92: 3566-3570.
  • 8Kobayashi S, Kishimoto T, Kamata S, Otsuka M, Miyazaki M, Ishikura H. Rapamycin, a specific inhibitor of the mammalian target of rapamycin, suppresses lymphangiogenesis and lymphatic metastasis. Cancer Sci 2007; 98: 726-733.
  • 9Fareed J, Hoppensteadt DA, Bick RL. An update on heparins at the beginning of the new millennium. Semin Thromb Hemost 2000; 26: 5-21.
  • 10Lebeau B, Chastang C, Brechot JM, Capron F, Dautzenberg B, Delaisements C, et al. Subcutaneous heparin treatment increases survival in small cell lung cancer. Cancer 1994; 74: 38-45.

共引文献58

同被引文献43

引证文献14

二级引证文献42

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部